Biological half-life is the time required for biological processes to reduce the amount of a specified substance in an organism, tissue, or body fluid to half its initial value. These processes include metabolism, excretion, and degradation. In pharmacokinetics, the term commonly refers to the elimination half-life of a drug, often estimated from its concentration in blood plasma. In radiation protection, it describes removal of a radioactive substance by biological processes, separately from its loss through radioactive decay. A half-life is therefore meaningful only when the substance, the measured compartment, and the conditions of measurement are specified.
Biological basis
A substance may be removed from the body through urine, feces, exhaled air, or other routes. It may also undergo metabolism, becoming a different chemical substance before its products are excreted. For a parent drug, chemical transformation counts as elimination of that drug even if its metabolites remain in the body.
Biological half-life can describe several different measurements:
- Whole-body retention: the decline in the total amount of a substance present in the body.
- Tissue retention: the decline in the amount within a particular organ or tissue.
- Plasma elimination: the decline in a substance’s plasma concentration during an identified elimination phase.
These measurements are not interchangeable. Movement from blood into tissues can lower plasma concentration without removing the substance from the body. Conversely, a substance stored in tissues may continue entering the circulation after exposure has ended.
Mathematical description
First-order elimination
A constant half-life arises when elimination follows first-order kinetics: a constant fraction of the substance is removed per unit time. If is the amount remaining at time , then
where is the initial amount and is the elimination rate constant. The half-life is
After half-lives, the fraction remaining is
Thus, 50% remains after one half-life, 25% after two, and approximately 3.1% after five. This model approaches zero without reaching it mathematically; a statement that a substance has been “cleared” usually refers to a practical threshold, not absolute absence.
Clearance and distribution
For a simple one-compartment pharmacokinetic model with first-order elimination,
where is the volume of distribution and is clearance. Volume of distribution relates the amount of drug in the body to its plasma concentration; it is an apparent volume, not necessarily an anatomical space. Clearance expresses the body's elimination capacity as a volume of plasma effectively cleared of drug per unit time.
The equation shows that half-life depends on both distribution and elimination. A long half-life may result from low clearance, extensive tissue distribution, or both. It does not, by itself, establish how efficiently an organ removes the substance.
Multiple phases and nonconstant half-lives
Many substances do not follow a single exponential decline. After administration into the bloodstream, a drug may show an early, rapid fall in plasma concentration as it distributes into tissues, followed by slower phases involving elimination and release from tissue stores.
The terminal half-life is calculated from the final approximately straight portion of a concentration–time curve plotted on a logarithmic concentration scale. It may reflect slow redistribution as well as elimination. In multicompartment models, its relationship to clearance requires a distribution volume appropriate to the terminal phase rather than an arbitrary measure of distribution volume.
Other situations further limit the use of one half-life:
- Saturable elimination: when an elimination pathway approaches capacity, the fraction removed per unit time can change with concentration.
- Slow absorption: after some oral or depot formulations, the terminal decline may be governed by absorption rather than elimination, a pattern called flip-flop kinetics.
- Continued exposure or production: ongoing intake, release from a formulation, or endogenous synthesis can obscure the underlying elimination rate.
- Recirculation: reabsorption after secretion into bile can produce secondary concentration peaks and prolong persistence.
A reported half-life may therefore describe a particular phase and experimental setting rather than a fixed property of the substance.
Factors affecting biological half-life
Half-life can vary between individuals and within the same individual over time. Relevant factors include:
- Organ function. Reduced kidney function can decrease the clearance of substances eliminated through the kidneys. Liver disease can affect metabolism and biliary elimination.
- Age and physiological state. Development, aging, and pregnancy can alter body composition, organ function, and distribution volumes.
- Interactions. Other substances may inhibit or induce a metabolic enzyme, alter transport processes, or change excretion.
- Genetic variation. Differences in metabolic enzymes and transport proteins, studied in pharmacogenomics, can affect drug elimination.
- Tissue binding and storage. Accumulation in fat, bone, or other tissues can create slowly exchanging reservoirs.
- Concentration. Saturation of metabolism, transport, or binding can make half-life concentration-dependent.
These influences are substance-specific. A change in organ function does not necessarily alter every substance’s half-life in the same direction or to the same degree.
Radioactive substances
For a radioactive substance, biological removal and radioactive decay are distinct processes:
- Biological half-life describes removal from the body or a specified compartment through biological processes.
- Physical half-life describes the time required for half the radioactive nuclei to decay.
- Effective half-life describes the combined decline in retained radioactivity.
If biological removal and radioactive decay are independent first-order processes,
or equivalently,
For finite positive half-lives, the effective half-life is shorter than either component half-life. This relationship is important in nuclear medicine and radiation dosimetry. More complex models are needed when radioactive material moves between tissues, has several biological retention components, or produces radioactive daughter products.
Applications and interpretation
In drug development, half-life helps characterize persistence, accumulation during repeated administration, and the time course after administration stops. Under linear, time-invariant conditions, approximately four to five relevant half-lives are required to complete about 94–97% of the approach to a new steady state or of the decline after input ceases. Multicompartment behavior can complicate this approximation.
Half-life is not the same as duration of action. Pharmacodynamics also depends on active metabolites, receptor binding, delayed physiological responses, and changes that persist after a drug has disappeared from plasma. A short plasma half-life can therefore coexist with a longer biological effect.
In environmental and occupational studies, biological half-life helps characterize retention of absorbed contaminants. Interpretation must distinguish a single exposure from repeated exposure and specify whether the measurement concerns the parent substance, a metabolite, or total retained material.
Reported values also depend on sampling duration, analytical sensitivity, and the model fitted to the observations. Sparse or short-term sampling may miss a slow terminal phase. A measured plasma half-life does not necessarily establish tissue persistence, duration of effect, or the time until a substance becomes analytically undetectable.